Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04283890 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PHP and Immunotherapy in Metastasized UM

Study acronym: CHOPIN
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 2025 to Dec 2026 Completion date: Aug 2025 to Dec 2029v4 Show 1 more changeShow less
    • Completion date: Aug 2025 to Dec 2029
  2. Primary and study completion dates: Dec 1, 2024 to Aug 2025 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv3 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  3. Enrollment target: 88 to 83 Eligibility criteria expanded, about 14 words · Site contact updatedv2 Show 2 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with nivolumab) and chemotherapy (melphalan) will be assessed for the treatment of disseminated uveal melanoma. Melphalan will be administered selectively to the liver via percutaneous hepatic perfusion, limiting the systemic effect of chemotherapy. With this treatment combination we aim to find a treatment for disseminated uveal melanoma, both in the liver as in the other organs.
Trial Details
NCT Number NCT04283890
Lead Sponsor Leiden University Medical Center
Conditions Uveal Melanoma, Metastatic
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov